[Skip to Content]
[Skip to Content Landing]
August 28, 2002

Antimicrobial Therapy in Patients With Escherichia coli O157:H7 Infection

Author Affiliations

Author Affiliations: Statens Serum Institut, Copenhagen, Denmark (Dr Mølbak); and the Centers for Disease Control and Prevention, Atlanta, Ga (Drs Mead and Griffin).

JAMA. 2002;288(8):1014-1016. doi:10.1001/jama.288.8.1014

Shiga toxin–producing Escherichia coli O157:H7 is an important cause of enteric illness in developed countries.1 Infection typically presents as a diarrheal illness, often with bloody stools. In approximately 8% of patients,2 infection progresses to hemolytic uremic syndrome (HUS), a life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.